Drugs Targeting MET
- Tabrecta (capmatinib) – approved for stage 4 NSCLC patients with a MET exon 14 skipping change as detected by a biomarker test.
- Tepmetko (tepotinib) – approved for stage 4 NSCLC patients with a MET exon 14 skipping change as detected by a biomarker test.